ArticleCell & bioscience2026
TGF-β1/SMAD signaling downregulates KLF4 expression via direct transcriptional suppression and FAT10-mediated proteasomal degradation in hepatocellular carcinoma.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Designed Minibinders Rewire Receptor Signaling to Enable Functional Human Myogenic Reprogramming.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLoss of tumor suppressor Krüpple-like factor 4 (KLF4) expression in hepatocellular carcinoma (HCC) is crucial for aggressive tumor progression and poor patient prognosis. However, the mechanisms underlying KLF4 loss in human HCC are poorly characterized. Here, we explore the mechanisms by which canonical TGF-β1 signaling suppresses KLF4 in HCC.
methodsThe expression and correlation of KLF4, FAT10 and phospho-SMAD2/3 (pSMAD2/3) were evaluated by using tissue microarray and immunohistochemistry. Cellular and molecular impacts of TGF-β1 signaling on FAT10 and KLF4 expression as well as the interaction between FAT10 and KLF4 were determined using western blot, quantitative real-time PCR, chromatin immunoprecipitation, reporter promoter assay, co-immunoprecipitation and immunofluorescence.
resultsWe found that elevated p-SMAD2 and p-SMAD3 expression correlated with increased FAT10 but decreased KLF4 expression in primary HCC. High p-SMAD2 and p-SMAD3 expression also associated with reduced overall and recurrence-free survival after surgery in HCC. Activation of TGF-β1 signaling in HCC cells transcriptionally upregulated FAT10, but downregulated KLF4 expression. Mechanistically, activation of TGF-β1 signaling enhanced the direct binding of SMAD2/3 to FAT10 and KLF4 promoter. Furthermore, FAT10 directly interacted with KLF4 protein, and deletion of the C-terminal diglycine motif of FAT10 or the Zinc-finger domain of KLF4 abrogated the interaction. Moreover, FAT10 promoted KLF4 proteasomal degradation in a ubiquitin-independent manner in HCC cells.
conclusionsOur data suggest that active TGF-β1/SMAD signaling contributes to the loss of KLF4 expression in human HCC through FAT10-mediated ubiquitin-independent proteasomal degradation and direct transcriptional suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.